Single-sample GSEA using pyroptotic gene Signature score (S-score) revealed that the majority of responding tumors tend to have a positive S score while most non-responsive tumors, if not all, are negative for S-score in several cohorts of melanoma patients and one cohort of patients with gastric cancer67–71 (Fig. 7g and Supplementary Fig. 7a, c, d), indicating that tumors with high expression of pyroptotic gene signature correlate with a stronger response to PD-1-PD-L1 checkpoint blockade therapies. Here, CD274 is linked to melanoma.